Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Bachy

Showing results (81-90 of 176) with videos related to

Pageof 18
Sort By:
American Journal of Hematology|January 23, 2016
Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort studyEmmanuel Bachy, Jane A Estell, Eric Van de Neste, et al.
Genes, Chromosomes & Cancer|November 2, 2016
Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disordersClémentine Sarkozy, Sophie Kaltenbach, Pierre Faurie, et al.
Haematologica|May 30, 2024
Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targetsPierre Stephan, Jimmy Perrot, Allison Voisin, et al.
Leukemia|March 14, 2023
Exploring the genetic landscape of HCV-related B-cell lymphomas using whole exome sequencingMarine Armand, Michaël Degaud, Bruno Tesson, et al.
Leukemia & Lymphoma|November 1, 2021
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective studyGuillaume Aussedat, Delphine Maucort-Boulch, Philippe Rey, et al.
Biomarker Research|September 13, 2024
18F-FDG PET/CT metrics-based stratification of large B-cell lymphoma receiving CAR-T cell therapy: immunosuppressive tumor microenvironment as a negative prognostic indicator in patients with high tumor burdenLing-Shuang Sheng, Rong Shen, Zi-Xun Yan, et al.
Annals of Hematology|November 21, 2019
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemiaGilles Salles, Emmanuel Bachy, Lukas Smolej, et al.
Haematologica|November 28, 2024
Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphomaLorenzo Falchi, Martin Hutchings, Carmelo Carlo-Stella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II StudyTycel Jovelle Phillips, Carmelo Carlo-Stella, Franck Morschhauser, et al.
Blood Advances|May 1, 2025
TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomasPierre Stephan, Roberta Di Blasi, Louise Roulin, et al.
Pageof 18

Showing results (81-90 of 176) with videos related to

Sort By:
Pageof 18
American Journal of Hematology|January 23, 2016
Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort studyEmmanuel Bachy, Jane A Estell, Eric Van de Neste, et al.
Genes, Chromosomes & Cancer|November 2, 2016
Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disordersClémentine Sarkozy, Sophie Kaltenbach, Pierre Faurie, et al.
Haematologica|May 30, 2024
Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targetsPierre Stephan, Jimmy Perrot, Allison Voisin, et al.
Leukemia|March 14, 2023
Exploring the genetic landscape of HCV-related B-cell lymphomas using whole exome sequencingMarine Armand, Michaël Degaud, Bruno Tesson, et al.
Leukemia & Lymphoma|November 1, 2021
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective studyGuillaume Aussedat, Delphine Maucort-Boulch, Philippe Rey, et al.
Biomarker Research|September 13, 2024
18F-FDG PET/CT metrics-based stratification of large B-cell lymphoma receiving CAR-T cell therapy: immunosuppressive tumor microenvironment as a negative prognostic indicator in patients with high tumor burdenLing-Shuang Sheng, Rong Shen, Zi-Xun Yan, et al.
Annals of Hematology|November 21, 2019
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemiaGilles Salles, Emmanuel Bachy, Lukas Smolej, et al.
Haematologica|November 28, 2024
Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphomaLorenzo Falchi, Martin Hutchings, Carmelo Carlo-Stella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2024
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II StudyTycel Jovelle Phillips, Carmelo Carlo-Stella, Franck Morschhauser, et al.
Blood Advances|May 1, 2025
TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomasPierre Stephan, Roberta Di Blasi, Louise Roulin, et al.
Pageof 18